Browsing by Author "Rasmussen, Line D (35316497000)"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Clinical Outcomes in Persons Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment(2020) ;Mocroft, Amanda (7006513758) ;Lundgren, Jens (35307337700) ;Gerstoft, Jan (7005184715) ;Rasmussen, Line D (35316497000) ;Bhagani, Sanjay (8203699300) ;Aho, Inka (36436796700) ;Pradier, Christian (57208854241) ;Bogner, Johannes R (7005719945) ;Mussini, Christina (7006842875) ;Uberti Foppa, Caterina (7004830366) ;Maltez, Fernando (6602422083) ;Laguno, Montse (35780408100) ;Wandeler, Gilles (24175415100) ;Falconer, Karolin (24278383500) ;Trofimova, Tatyana (59060501200) ;Borodulina, Elena (6603123975) ;Jevtovic, Djordje (55410443900) ;Bakowska, Elzbieta (6506711431) ;Kase, Kerstin (57216676281) ;Kyselyova, Galina (56817102800) ;Haubrich, Richard (57210200091) ;Rockstroh, Jürgen K (57207907471) ;Peters, Lars (15058026800) ;Losso, M. (56785746500) ;Schmied, B. (25621923500) ;Karpov, I. (15832060600) ;Clumeck, N. (55666222200) ;Hadziosmanovic, V. (59832066000) ;Begovac, J. (7004168039) ;Machala, L. (6602134360) ;Zilmer, K. (6603989068) ;Viard, J.-P. (7006656190) ;Chkhartishvili, N. (25227423400) ;Sambatakou, H. (57201621059) ;Szlávik, J. (6602551338) ;Gottfredsson, M. (57219095311) ;Mulcahy, F. (7005651577) ;Tau, L. (36573068100) ;D'Arminio Monforte, A. (7006907326) ;Rozentale, B. (8864942800) ;Uzdaviniene, V. (56884779800) ;Staub, T. (56992899600) ;Reiss, P. (55864802000) ;Reikvam, D.H. (35176496200) ;Knysz, B. (57216330515) ;Caldeira, L. (6602208012) ;Radoi, R. (56884532300) ;Panteleev, A. (56817093100) ;Dragovic, G. (23396934400) ;Tomazic, J. (6603749556) ;Miró, J.M. (57215499114) ;Scherrer, A. (35308020900)Gazzard, B. (57197156497)Background: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. Methods: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). Results: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured. Conclusions: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining he importance of successful HCV treatment for reducing ESLD. © 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.